# AMT-191 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/amt-191

> AMT-191, sponsored by uniQure N.V. (QURE): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AMT-191 |
| Codes | AMT-191 |
| Sponsor | uniQure N.V. (QURE) https://sec-api.dev/companies/qure/catalysts |
| Indications | [fabry disease](https://sec-api.dev/indications/fabry-disease) |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Nov 2023: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-02-27, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001104659-26-021898): "In November 2023, the FDA cleared the IND application, and we began incurring additional costs for Phase I/II clinical trial preparation." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001699): "In November 2023, the FDA cleared the IND application, and we started incurring additional costs for Phase I/II clinical trial preparation." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001699/qure-20241231x10k.htm

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: Fabry disease.
- First seen 2025-02-27, last confirmed 2025-07-29.
- SEC Form 10-Q (accession 0001558370-25-009694): "In August 2024, we announced that the first patient has been dosed." https://www.sec.gov/Archives/edgar/data/1590560/000155837025009694/qure-20250630x10q.htm
- SEC Form 10-K (accession 0001558370-25-001699): "In August 2024, we announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001699/qure-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001699): "In August 2024, we announced that the first patient was dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001699/qure-20241231x10k.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-02-27, last confirmed 2025-05-09.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007065): "The Company plans to present initial data from the study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001693): "The Company expects to initiate enrollment in the second dose cohort in the second quarter of 2025 and to present initial data from the study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1. Indication: Fabry disease.
- First seen 2025-11-10, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-108802): "~ Presented initial data from Phase I/IIa study of AMT-191 in Fabry disease showing sustained increases in α - gal enzyme activity in patients with Fabry disease; additional clinical data expected in the first half of 2026 ~" https://www.sec.gov/Archives/edgar/data/1590560/000110465925108802/qure-20251110xex99d1.htm

## Same indication

- [Elfabrio (pegunigalsidase alfa)](https://sec-api.dev/pdufa/pegunigalsidase-alfa) (PLX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/amt-191.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMT-191 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/amt-191

```bibtex
@misc{secapidev_pdufa_amt_191_20261116,
  title        = {AMT-191 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/amt-191}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_amt_191_20261116","title":"AMT-191 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/amt-191","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
